Abstract: The present invention relates to immunoglobulin (Ig) binding proteins comprising one or more Ig binding domains with amino acids selected from the group consisting at least of 1I, 11A, 11E, 11I, 35R, 35I, and 42L. The invention further relates to affinity matrices comprising the Ig binding proteins of the invention. The invention also relates to a use of these Ig binding proteins or affinity matrices for affinity purification of immunoglobulins and to methods of affinity purification using the Ig binding proteins of the invention.

Abstract: Chimeric transmembrane immunoreceptors (CAR) which include an extracellular domain that includes chlorotoxin or a related toxin, or a variant of chlorotoxin or a related toxin, that binds to human glioma or other human tumor cells, a transmembrane region, a costimulatory domain and an intracellular signaling domain are described.

Abstract: An isolated peptide is provided. The peptide comprises an amino acid sequence arranged in a space and configuration that allow interaction of the peptide with the DNA Binding Domain (DBD) of p53 through at least one residue of the DBD by which pCAP 250 (SEQ ID NO: 1) binds the DBD, wherein the peptide at least partially reactivates a mutant p53 protein, with the proviso that the peptide is not SEQ ID NO: 59-382.

Abstract: The present invention provides an antagonist of a Bcl-2 prosurvival protein containing a BH3-like domain. The antagonist of the invention comprises ARTS and any fragment or peptide that comprises a BH3-like domain. The invention further provides compositions, combined compositions and kits as well as methods for treating Bcl-2 over-expressing disorders.

Abstract: Described herein are recombinant chimeric proteins comprising a double stranded RNA (dsRNA) binding domain and a cancer-cell targeting domain for targeting of dsRNA to cancer cells. Methods of use of the described chimeric proteins are also provided herein.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present invention relates to polypeptide variants of human fibroblast growth factor 21 (FGF21) and fusion molecules thereof, as well as to nucleic acid molecules encoding the same. It further relates to their use as medicaments, in particular for the treatment of obesity, overweight, metabolic syndrome, diabetes mellitus, hyperglycemia, dyslipidemia, non-alcoholic steatohepatitis (NASH) and/or atherosclerosis.

Abstract: The present invention relates to inhibin analogs, their method of production and their use in the treatment and prophylaxis of disease or conditions associated with reduced levels of inhibin and activin-mediated signaling.

Abstract: This disclosure provides GLP-1/glue agon agonist peptides for the treatment of metabolic diseases, e.g., obesity.

Abstract: A first aspect of the invention relates to a polypeptide compound of formula (I): A-C-B??(I) wherein: A is the A chain of insulin or a functional derivative or variant thereof; B is the B chain of insulin or a functional derivative or variant thereof; C is a peptide of the formula: (X1)p-(X2)n-(X3)q wherein: each X1 and X3 is independently a basic amino acid; each X2 is independently a natural or unnatural amino acid; p is 1 or 2; q is 0, 1 or 2; n is 0, 1, 2 or 3. Further aspects of the invention relate to pharmaceutical compositions comprising said polypeptide compound, and therapeutic uses thereof. Another aspect relates to the use of said polypeptide compounds in the preparation of insulin and derivatives thereof.

Abstract: The method of producing induced lightweight exosomes (iLE) provided by the present invention includes preparing a cell culture containing prescribed cultured cells; supplying at least once an artificially produced synthetic peptide to the cell culture and culturing the cell culture for a prescribed interval; and obtaining exosomes produced by the cultured cells following culturing. Here, the synthetic peptide is provided with: (1) an exosome-inducing peptide sequence and (2) a CPP sequence, and has a total number of amino acid residues of 100 or less.

Abstract: A novel use of ligands of B7h receptor in the treatment of osteoporosis or osteopenia is disclosed as well as the use of B7h receptor as target for the screening of pharmaceutical active agents useful in the treatment of osteopenia or osteoporosis.

Abstract: Provided herein are variant CD80 polypeptides, immunomodulatory proteins comprising variant CD80 polypeptides, and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological and oncological conditions. Compositions and methods for making and using such proteins are provided.

Abstract: Novel fusion molecules and uses are disclosed.

Abstract: In one aspect, the present invention is directed to a method for preventing or treating necrotic enteritis by administering a hyperimmunized egg product obtained from an egg-producing animal to an avian. The hyperimmunized egg product may contain an antibody specific to an antigen selected from the group consisting of Clostridium perfringens ?-toxin, Clostridium perfringens elongation factor Tu (EF-Tu), Clostridium perfringens necrotic enteritis B-like (NetB) toxin, Clostridium perfringens Pyruvate: Ferredoxin oxidoreductase (PFO), and Eimeria tenella elongation factor 1-alpha.

Abstract: The present invention is directed to antigen binding proteins including, but not limited to, monoclonal antibodies and antigen binding fragments thereof, that specifically bind to and preferably neutralize human cytomegalovirus (CMV). The antigen binding proteins of the invention are useful as a prophylactic and/or therapeutic agent for preventing and/or treating CMV infections in a patient in need thereof. Also encompassed by the invention are pharmaceutical compositions comprising the antigen binding proteins of the invention and a pharmaceutically acceptable carrier. The invention further relates to methods of using the antigen binding proteins and pharmaceutical compositions of the invention for the prevention or treatment of CMV infection in patients in need thereof.

Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody to a Middle East Respiratory Syncytial Coronavirus (MERS-CoV) viral antigen. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating an MERS-CoV virus infection in a subject using said composition and method of generation.

Abstract: This disclosure relates to binding agents, e.g., antibodies and antigen-binding fragments thereof, that bind hemagglutinin protein of influenza viruses, and methods of their use.

Abstract: It is provided novel anti-galactofuranose antibodies and their use for diagnosis of and/or treating aspergillosis, and for the design of chimeric antigen receptor T-cells, wherein single chain variable fragment of the antibodies, such as a heavy chain variable region or a light chain variable region, is fused via a spacer and a transmembrane domain to a signaling endodomain to generate an expression cassette that will be integrated into a T cell.

Abstract: The present invention provides methods for treating and improving the symptoms of osteogenesis imperfecta (OI) in a subject by administering to the subject a therapeutically effective amount of a binding agent that binds to transforming growth factor beta (TGF?).

Abstract: Methods for enhancing the immune response and/or treatment of diseases such as cancer comprising an agent that specifically binds TIGIT are disclosed. The TIGIT-binding agents may include polypeptides, antibodies, and/or bispecific agents.

Abstract: The invention encompasses methods of treatment of interferon gamma (IFN-?)-mediated diseases using IFN-? inhibitors, such as anti-huIFN-? antibodies, wherein levels of expression of one or more biomarkers are determined either before administration of the IFN-? inhibitor and/or after administration. Also contemplated are methods of treatment using particular, pharmacodynamically effective doses of an anti-huIFN-? antibody.

Abstract: Provided are methods involving combination therapy comprising administering to an individual in need thereof an antibody that preferentially depletes human B10 cells and an immune checkpoint inhibitor. Antibodies for use in the methods are also provided.

Abstract: The present invention encompasses the discovery that the likelihood of a favorable response to cancer immunotherapy for a wide range of different cancers can be predicted through definition of a tumor mutational load threshold for the tumor (and/or the relevant immunotherapy).

Abstract: The invention provides anti-B7-H4 antibodies and immunoconjugates and methods of using the same.

Abstract: Provided herein are antibodies which bind to latency-associated peptide (LAP) of TGF-?1 and are characterized by particular functional features, such as binding specifically to LAP-TGF?1 on cells but not to LAP-TGF?1 in extracellular matrix, as well as compositions including the same. Also provided are uses of these antibodies in therapeutic applications, such as in the treatment of cancer, and diagnostic applications.

Abstract: The description concerns humanized antibodies directed against the extracellular domain of the alpha chain of the receptor for interleukin-7 (IL-7), especially against the receptor for human IL-7 expressed on human cells (also designated human IL-7Ralpha or IL-7Ra or CD127) and which do not interfere with the IL-7 or TSLP signaling pathways. The antibodies described do not have an antagonistic effect on the IL-7 receptor, but may still present cytotoxic activity against CD127 positive cells. In a particular embodiment, the antibody does not have an agonist effect on the IL-7 receptor.

Abstract: The present invention relates to a protein binding to GARP in the presence of TGF-? and uses thereof.

Abstract: Isolated monoclonal antibodies which bind to human CD38 and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies.

Abstract: The present invention relates to humanized antibodies that specifically bind to human transferrin receptor and their use in treating cancer and inflammatory disorders.

Abstract: Humanized antibody to a pathologically mislocated form of N-cadherin detects and eliminates cells that express the protein extracellularly. These cells are found in fibrotic conditions within heart, lung, and liver, as well as kidney, skin, and other organs effected by fibrosis. The antibody does not affect cells with normal, subcellular location of the protein.

Abstract: Methods are provided for treating a subject with for an intracellular pathogen infection, by administering an agent that reduces the binding of CD47 on a infected cell to SIRP? on a host phagocytic cell, in an effective dose for increasing the phagocytosis of infected cells.

Abstract: The present disclosure provides antibodies, or an antigen binding portion thereof, that bind to sLeA and sLeC, as well as polynucleotides, vectors, host cells, pharmaceutical compositions, and methods related thereto.

Abstract: The present invention provides antibody polypeptides with binding specificity for human kallikrein-2 (hK2), wherein the antibody polypeptide comprises (a) a heavy chain variable region comprising the amino acid sequences of SEQ ID NO:1 and SEQ ID NO:2 and SEQ ID NO:3 and/or (b) a light chain variable region comprising the amino acid sequences of SEQ ID NO:4 and SEQ ID NO:5 and SEQ ID NO:6, and wherein the heavy chain variable region and light chain variable region comprise framework amino acid sequences from one or more human antibodies. The invention further provides use of said antibody polypeptides in the diagnosis and treatment of prostate cancer.

Abstract: The invention provides bivalent antibodies including two light and heavy chain pairs. The N-termini of one or both light and heavy chain pairs are linked via linkers comprising a protease cleavage site to coiled-coil forming peptides that associate to form a coiled coil reducing binding affinity of at least one light-heavy chain pair to a target.

Abstract: The present invention concerns an improved process for biorefinery of brown macroalgae, which comprises: (a) contacting the brown macroalgae with a solvent system comprising at least 30 wt % organic solvent, to obtain extracted macroalgae as solid residue and a liquor; and (b) biorefining the extracted macroalgae. The inventors have found that the contacting of step (a) results in an efficient and cost-effective dewatering of the macroalgae, wherein up to 95 wt % of the internal moisture of the macroalgae could be lost without the need for energy-consuming drying techniques. As such, the downstream biorefinery of the extracted macroalgae is greatly facilitated.

Abstract: Embodiments of the present invention are directed to kits, compositions and methods for modifying and altering polysaccharide fillers and drug delivery systems with the application of hyaluronidase.

Abstract: Systems and methods for extracting useful by-products and natural rubber from non-Hevea rubber bearing plants are disclosed.

Abstract: Methods for reducing gels and/or dome sheeting in gas phase polymerization processes and their resulting products are provided. The polymerization processes include polymerizing ethylene and one or more optional comonomers in a fluidized bed reactor in the presence of a metallocene catalyst, hydrogen, and at least one condensing agent.

Abstract: A formulation for a photopolymer composite material for a 3D printing system includes an acrylate monomer or an acrylate oligomer, an inorganic hydrate, a reinforcing filler, a co-initiator, a thermal initiator, and an ultraviolet (UV) initiator. In the formulation the acrylate monomer or the acrylate oligomer may be between about 10.0-30.0 w % of the formulation. The thermal initiator may be between about 0.001-0.05 w %, the co-initiator may be between about 0.001-0.05 w %, and the UV initiator may be between about 0.001-0.2 w % of the formulation. A method of generating a formulation of a photopolymer composite material for use in a 3D printing system includes using an acrylate monomer or an acrylate oligomer, an inorganic hydrate, a reinforcing filler, a co-initiator, a thermal initiator, and an ultraviolet (UV) initiator.

Abstract: A composition contains ethylenically unsaturated quaternary ammonium cations with acetate counterions, where each of the ethylenically unsaturated ammonium cations contain only one non-aromatic carbon-carbon double bond and the composition contains less than one mole-percent chloride relative to quaternary ammonium cations can be polymerized to form a cationic polymer acetate.

Abstract: A resin composition contains a 2-methylene-1,3-dicarbonyl compound and an initiator. The 2-methylene-1,3-dicarbonyl compound has a molecular weight of 180 to 10,000, and the initiator contains a basic substance having a pKa of 8 or greater.

Abstract: The present invention relates to a modifier represented by Formula 1, a method of preparing the same, a modified conjugated diene-based polymer having a high modification ratio which includes a modifier-derived functional group, and a method of preparing the polymer.

Abstract: A curable composition contains: a cardo skeleton-containing monomer having two or more (meth)acryloyl groups in a molecule; an aromatic ring-containing monofunctional (meth)acrylate monomer; and an acidic phosphate ester, in which the acidic phosphate ester is a compound represented by General Formula (1), and the content of the acidic phosphate ester is 0.003% to 1% by mass with respect to a total mass of the curable composition.

Abstract: An organic polymer comprising an organic polymer fragment and at least one S-alkylsilyl hydrocarbonthioate group or at least one S-alkylstannyl hydrocarbonthioate group bonded to the backbone of the organic polymer fragment through a C—Si covalent bond and their methods or production are provided. The organic polymer backbone can be derived from the anionic polymerization of monomers containing C—C unsaturation. The silicon or tin atom can be further bonded to two alkoxy groups, two hydrocarbon groups or to one alkoxy group and one hydrocarbon group.

Abstract: A curable polymer latex composition obtainable by: (a) subjecting a monomer mixture comprising i. at least one conjugated diene; ii. at least one ethylenically unsaturated nitrile; iii. optionally at least one ethylenically unsaturated acid; iv. optionally at least one further ethylenically unsaturated compound different from any of the compounds (i)-(iii); to free-radical emulsion polymerization in an aqueous reaction medium to form a raw polymer latex; and (b) allowing the obtained raw latex to mature in the presence of at least one thiocarbonyl-functional compound, wherein the at least one thiocarbonyl-functional compound is present in an amount of at least 0.05 wt.-%, based on the total amount of monomers subjected to free-radical emulsion polymerization in step (a), and (c) optionally compounding the matured polymer latex with one or more cross-linking agent. Methods for making such curable polymer latex composition or rubber articles made therefrom, respectively.

Abstract: A vulcanizable composition comprising rubber component, a filler, and a curing agent, where the rubber component includes a block copolymer of polybutadiene and polyisoprene, and where the block copolymer has a cis content of at least 90%.

Abstract: The present invention relates to a phenolic resin for use in the phenolic resin component of a two-component binder system for the polyurethane cold box process, to a two-component binder system for use in the polyurethane cold box process, to a molding material mixture for curing by contacting with a tertiary amine, to the use of a corresponding phenolic resin, of a corresponding phenol component, of a corresponding two-component binder system or of a corresponding molding material mixture. The present invention relates, moreover, to an article from the group consisting of feeders, foundry molds and foundry cores, producible from a corresponding molding material mixture, to a process for preparing a phenolic resin, and to a process for producing an article from the group consisting of feeders, foundry molds and foundry cores.

Abstract: Embodiments in accordance with the present invention encompass compositions containing a latent catalyst and a compound capable of generating a Bronsted acid with a counterion capable of coordinating and activating the latent catalyst along with one or more monomers which undergo ring open metathesis polymerization (ROMP) when said composition is exposed to a suitable radiation to form a three-dimensional (3D) object. The catalyst system employed therein can be sensitive to oxygen and thus inhibits polymerization in ambient atmospheric conditions. The three-dimensional objects made by this process exhibits improved mechanical properties, particularly, high distortion temperature, impact strength, elongation to break, among others. Accordingly, compositions of this invention are useful as 3D inkjet materials for forming high impact strength objects of various sizes with microscale features lower than 100 microns, among various other uses.

Abstract: Described herein are methods of preparing poly(alkylene carbonate) polymers comprising an increased ratio of primary hydroxyl end groups to secondary hydroxyl end groups, and compositions thereof.